Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.46 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 3/20 | 0.40 |
| ▸ | PTGES | O14684 | 2/20 | 0.40 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL617022 | 0.91 | TTR (0.45) | MRGPRX4RORCTTRPLA2G2DSLC16A3 | |
| SCHEMBL617233 | 0.85 | HTR5A (0.57) | HTR5A | |
| Hydrochloric Acid SCHEMBL617389 | 0.84 | HTR5A (0.56) | HTR5A | |
| SCHEMBL615007 | 0.83 | MRGPRX4 (0.37) | MRGPRX4KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL10064303 | 0.83 | LMNA (0.45) | MRGPRX4HTR5AALDH1A1 | |
| SCHEMBL10063691 | 0.81 | CSNK2A2 (0.41) | MRGPRX4RORCTTRPLA2G2DSLC16A3 | |
| SCHEMBL10064300 | 0.81 | KDM4E (0.41) | MRGPRX4TTRKDM4EMEN1ALDH1A1 | |
| SCHEMBL10064017 | 0.81 | SLC22A12 (0.39) | MRGPRX4PLA2G2DHTR5ASLC16A3ALDH1A1 | |
| SCHEMBL7916729 | 0.81 | SLC22A12 (0.42) | MRGPRX4RORCPPARGTTRPLA2G2D | |
| SCHEMBL7920119 | 0.81 | PLA2G2D (0.44) | MRGPRX4RORCPPARGTTRPLA2G2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | ASTELLAS PHARMA INC. (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | ASTELLAS PHARMA INC. (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2394988-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | HTR5A, HTR2A, HTR1A | MRGPRX4 2803/4885RORC 3123/4885PPARG 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.